TITLE

In Brief

AUTHOR(S)
L.F.; A.B.; J.F.
PUB. DATE
April 2002
SOURCE
Nature Biotechnology;Apr2002, Vol. 20 Issue 4, p327
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on various biotechnology business and regulatory news as of April 2002. Elan Corp.'s termination of clinical trials of its experimental vaccine for the treatment of Alzheimer's disease; Naming of Lester Crawford as deputy commissioner of the U.S. Food and Drug Administration; Biotechnology resources Web site for law clerks, judges and jurors.
ACCESSION #
8782218

 

Related Articles

  • Washington Insider. Dickinson, James G. // Medical Marketing & Media;Nov2001, Vol. 36 Issue 11, p28 

    Reports developments related to pharmaceutical industry in the U.S. as of November 2001. Nomination for director of Food and Nutrition Policy Lester Crawford as commissioner of the Food and Drug Administration (FDA); Responsibility of drug sponsors to monitor foreign-based clinical trials;...

  • Labor Pains and Gains. Russell, John // Bio-IT World;Sep2005, Vol. 4 Issue 9, p50 

    Presents several issues to watch out for in the biotechnology industry in the U.S. as of September 2005. Concerns in the pharmaceutical industry; Efforts of several biotechnology companies to engage in research programs on systems biology; Program initiated by Lester Crawford, successor to U.S....

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Sep2004, Vol. 39 Issue 9, p16 

    The article focuses on the drug and biotech products, which can be reformed by good manufacturing practices. Appearing before the Health Institutional Investor Conference in July, FDA, acting commissioner, Lester Crawford addressed a roomful of heavy contributors to U.S. President George W. Bush...

  • Regulatory news.  // Applied Clinical Trials;Sep2004, Vol. 13 Issue 9, p18 

    Reports on news and development concerning the field of clinical trials. U.S. Food and Drug Administration (FDA) Commissioner Lester M. Crawford's speech about the chance of success for a pharmaceutical company entering Phase 1 trials; FDA proposal to issue a complete response letter to an...

  • WASHINGTON INSIDER: Update.  // Medical Marketing & Media;Sep2007, Vol. 42 Issue 9, p18 

    The article offers news briefs concerning the pharmaceutical industry in the U.S. Senators Max Baucus and Chuck Grassley told that Food and Drug Administration (FDA) continues to suppress scientific dissent and punish agency staff who raise safety issues. FDA has ordered a clinical hold on a...

  • Pessimistic response to FDA leadership change. Kling, Jim // Nature Biotechnology;Nov2005, Vol. 23 Issue 11, p1325 

    Reports on the reaction of the biotechnology companies to the appointment of Andrew von Eschenbach as acting U.S. Food and Drug Administration commissioner following the resignation of Lester Crawford. Observation of apparent conflict of interest; Career history of interim agency head;...

  • BIOTECH. Webb, Marion // San Diego Business Journal;3/7/2005, Vol. 26 Issue 10, p9 

    The article presents information related to biotechnology. Cambridge, Massachusetts-based Biogen Idec Inc., the nation's third-largest biotechnology company, and its Irish pharmaceutical partner, Elan Corp., said last week that they had suspended sales and stopped using the drug Tysabri in...

  • CLINIC ROUNDUP.  // BioWorld Today;9/8/2008, Vol. 19 Issue 174, p3 

    This section offers news briefs on biotechnology in the U.S. Biogen Idec Corp. and Elan Corp. PLC has started a Phase I/II trial of Tysbari in patients with relapsed or refractory multiple myeloma. Cytokinetics Inc. began its third Phase IIa trial of CK-1827452, a cardiac myosin activator in...

  • CLINIC ROUNDUP.  // BioWorld Today;10/29/2009, Vol. 20 Issue 209, p7 

    This section offers news briefs on the biotechnology industry as of October 2009. The New England Institutional Review Board has allowed Advaxis Inc. to conduct a Phase II trial of ADXS11-001 in cervical dysplasia. BioInvent International AB and ThromboGenics NV have completed recruitment for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics